04.04.2017 • Topics

We Actively Face the Challenges

Peter Overlack, Co-CEO, Overlack Group
Peter Overlack, Co-CEO, Overlack Group

“It has always been a tradition at Overlack Group to actively deal with ongoing developments, gather information and if necessary react. We began analyzing our processes very early on and have been exploiting the advantages of digitalization. With an internal team, supported by external expertise, we defined areas that we can make more efficient through digitalization, for example storage and logistics, procurement and distribution. However, we also realize that internal processes such as in-company communication, HR and administration could be more efficient as well. Here we see great potential for making our company more agile and resilient.

We also take things one step further and have asked ourselves what the business model of a distributor could be like in the future. Here again, we actively face the challenges and analyze the possibilities of disruptive changes to the chemical distribution market, for example market or industry platforms. That’s where we see the biggest challenges. At the same time it is also a big chance to get closer to the customer and to offer more effective service.

In addition to all the developments in the area of digitalization, as always the important thing is the basics that make our company competitive, such as good Europe-wide coverage, a full-line portfolio with a focus on specialty chemicals and good customer-oriented services.”

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read